

Haematologica
HAEMATOL/2015/132431
Version 3

Phase I/II trial of Weekly Bortezomib with Lenalidomide and
Dexamethasone in First Relapse or Primary Refractory Myeloma

Annemiek Broijl, Marie-José Kersten, Wendimagegn Ghidey
Alemayehu, Mark-David Levin, Okke de Weerd, Edo Vellenga, Ellen
Meijer, Shulamit Wittebol, Bea C. Tanis, Petra B. Cornelisse, Marian
Stevens-Kroef, Gerard M.J. Bos, Pierre W. Wijermans, Henk Lokhorst,
and Pieter Sonneveld

Disclosures: M.J.K.: received research support from Celgene; attended advisory boards for Celgene and Janssen Pharmaceuticals. P.S. received research support from Celgene, Janssen, Millennium, Onyx. Received honoraria from Celgene, Janssen, Millennium, Onyx. E. V. received research support from Janssen. G.B. received research support from Celgene. H.L. attended advisory boards for Celgene and Janssen. A.B. attended advisory boards for Celgene and Amgen. W.G.A., M-D.L., O.W., E.M., S. W., B.T., P.C., M.S., P.W. have no disclosures

Contributions: Authorship Contribution: P.S. was the principal investigator; P.S., H. L., E.V. designed the research; all authors provided study materials or patients/ performed the research; W.G.A. performed statistical analyses; W.G.A., A.B, P.S. analyzed and interpreted the data; W.G.A., A.B., P.S. wrote the manuscript; and all authors reviewed the draft manuscript and approved the final version for submission